Liposomes block HIV infection in early tests; could be a cost-effective preventive for developing countries
September 19, 2011 - Boston, Mass.- HIV vaccines are in their infancy, and effective microbicides to prevent sexual
transmission of HIV still don't exist. Protection is especially needed for women, who make up nearly half of all global cases. Researchers
at Children's Hospital Boston envision a new way for women to protect
themselves before sex: an applicator filled with specially formulated fatty particles called liposomes.
In tests led by Daniel Kohane, MD, PhD, director of the Laboratory for Biomaterials and Drug Delivery at Children's
Hospital Boston, liposomes inhibited HIV infection in cell culture and appeared safe in female mice when injected intravaginally. The
findings are reported in the November issue of the journal Biomaterials, published online September 19.
Liposomes are spherical particles with a double outer layer of lipids (fats) and hollow centers. They are
relatively easy and cheap to engineer, and thus present a viable option for developing countries, where the cost of anti-HIV drugs
bars access for most people.
Liposomes can be filled with drugs or other compounds, but in this case, Kohane and colleagues found, to their
surprise, that the liposomes alone were effective in blocking infection.
"We had been planning do much more complex things, like putting ligands on the surface to increase binding to HIV," says Kohane. "It was
a surprise that liposomes alone worked so well. Simplicity is always better - if liposomes work by themselves, we may not need anything
else, and it would be cheaper and potentially much safer."
Kohane and colleagues hope to conduct further tests to better understand how the liposomes are blocking infection. They bind to HIV,
perhaps interfering with the virus's ability to fuse with cell membranes, the first step in infection.
"The idea, simplistically, is that liposomes look like cell membranes," says Kohane, "so maybe we could use them as decoys to prevent
Kohane and colleagues formulated a range of liposomes using various naturally occurring and synthetic lipids and screened
them systematically in cell cultures. Several formulations showed a good therapeutic profile, protecting the cells from HIV infection
without being toxic. Especially effective were liposomes containing cardiolipin, a fat that was first found in animal hearts;
performance was further improved by adding a synthetic phospholipid.
Tested in female mice, these formulations caused little or no inflammation, which can compromise the vaginal lining and
increase the risk of HIV transmission. Imaging confirmed that the liposomes remained in place or left the body, but did not travel
beyond the vagina.
"This research makes an important contribution towards creating a safe and effective form of HIV prevention for women," says
Nikita Malavia, PhD, the study's first author, who worked in Kohane's lab and in the lab of Robert Langer, ScD, of MIT. "Women in areas
such as sub-Saharan Africa often cannot control their male partners' use of condoms, making them three times more likely to be
HIV-positive than men. This technology could enable women to take control in their own hands."
Though some intravaginal compounds are in the pipeline, none are available yet. The advantage of using liposomes is that
they are inexpensive, easy to formulate into ointments or gels, and stable for long periods of time, making them a particularly good
option in resource-poor settings.
Kohane hopes to get further funding to test liposome formulations in other animal models.
The study was funded by the Grand Challenges in Global Health initiative and the National Institutes of Health.
Children's Hospital Boston
About Children's Hospital Boston
Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its
discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including nine members of the
National Academy of Sciences, 11 members of the Institute of Medicine and nine members of the Howard Hughes Medical
Institute comprise Children's research community. Founded as a 20-bed hospital for children, Children's Hospital
Boston today is a 396 bed comprehensive center for pediatric and adolescent health care grounded in the
values of excellence in patient care and sensitivity to the complex needs and diversity of children
and families. Children's also is the primary pediatric teaching affiliate of Harvard Medical
School. For more information about research and clinical innovation at Children's,
Source: Children's Hospital Boston
"Reproduced with permission - Children's Hospital Boston"
Children's Hospital Boston